Cyltezo
Named-patient access overview. Cyltezo is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cyltezo (adalimumab-adbm) is a subcutaneous anti-TNF monoclonal antibody developed by Boehringer Ingelheim. The US Food and Drug Administration approved Cyltezo as a biosimilar to Humira in August 2017 and designated it an interchangeable biosimilar in October 2021, with commercial launch in July 2023. Cyltezo is FDA-indicated across the adalimumab label, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. Maintenance dosing is typically 40 mg subcutaneously every other week, prescribed and monitored by a rheumatologist, dermatologist, gastroenterologist, or ophthalmologist.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cyltezo
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cyltezo is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Cyltezo in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cyltezo
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.